- Contact Us
The American Association of Nurse Practitioners® (AANP) is committed to providing members with up-to-date clinical and policy resources and information related to the COVID-19 pandemic and the U.S. national emergency declaration.
The FDA has approved the first COVID-19 vaccine: the Pfizer-BioNTech COVID-19 vaccine, which will now be marketed as Comirnaty, for the prevention of COVID-19 disease in individuals 16 years of age and older. Previously available under emergency use authorization (EUA), this Pfizer-BioNTech COVID-19 vaccine remains available for individuals 12 through 15 years of age and for the administration of a third dose in certain immunocompromised individuals under that EUA.
Previously, the FDA issued three EAUs to:
A joint statement was released on August 18 to add additional information on COVID-19 booster shots:
"The available data make very clear that protection against SARS-CoV-2 infection begins to decrease over time following the initial doses of vaccination, and in association with the dominance of the Delta variant, we are starting to see evidence of reduced protection against mild and moderate disease. Based on our latest assessment, the current protection against severe disease, hospitalization and death could diminish in the months ahead, especially among those who are at higher risk or were vaccinated during the earlier phases of the vaccination rollout. For that reason, we conclude that a booster shot will be needed to maximize vaccine-induced protection and prolong its durability.
“We have developed a plan to begin offering these booster shots this fall, subject to FDA conducting an independent evaluation and determination of the safety and effectiveness of a third dose of the Pfizer and Moderna mRNA vaccines and CDC’s ACIP issuing booster dose recommendations based on a thorough review of the evidence. We are prepared to offer booster shots for all Americans beginning the week of September 20 and starting 8 months after an individual’s second dose [...] We also anticipate booster shots will likely be needed for people who received the Johnson & Johnson (J&J) vaccine. Administration of the J&J vaccine did not begin in the U.S. until March 2021, and we expect more data on J&J in the next few weeks. With those data in hand, we will keep the public informed with a timely plan for J&J booster shots as well."
AANP is committed to ensuring that NPs have access to the latest COVID-19 vaccine information so they can educate patients on the importance of vaccination, and the association urges the public to get vaccinated at the earliest opportunity.
The CDC released a statement on the Janssen (Johnson & Johnson) COVID-19 vaccine following a thorough safety review related to six cases of a rare and severe type of blood clot that were reported in individuals who received the vaccine. The previously recommended pause regarding the use of the Janssen COVID-19 vaccine in the U.S. has been lifted and use of the vaccine has resumed.
The CDC is tracking the latest COVID-19 vaccine news and offers information about vaccine recommendations, how researchers are ensuring the safety of vaccines, how COVID-19 vaccines work and other details. The CDC also stresses the importance of COVID-19 vaccination for health care workers. A number of COVID-19 vaccine resources are now available, including:
In the U.S., 834,376,095 vaccine doses have been delivered, according to the CDC, with 263,415,633 people receiving at least one dose and 224,636,858 being fully vaccinated.
Among those who are fully vaccinated, 109,201,576 people have received their first booster dose while 22,495,442 people ages 50 and up have received the second booster dose.
AANP is a partner organization of the COVID-19 Vaccine Education and Equity Project, which raises awareness, provides education, promotes the impact of the COVID-19 vaccine and advocates for equitable access to authorized and approved vaccines. Use the #CountMeInCOVIDVx hashtag in all of your social media posts to promote the campaign and share your reason for be "counted in" for COVID-19 vaccination.
AANP is a founding member of the COVID-19 Community Corps, of which its We Can Do This campaign aims to increase COVID-19 vaccine confidence while reinforcing basic prevention measures. Learn more about how the campaign is educating the public and find resources for your community, including fact sheets, a podcast, toolkits, tip sheets, messages for social media and more.
AANP is a supporting organization of Keep Up The Rates, a national campaign launched by NFID to encourage all individuals to receive recommended vaccines that may have been delayed during the COVID-19 pandemic. This multimedia campaign engages national experts and leading public health organizations to reach populations who are most at risk of delaying vaccinations or of experiencing complications from vaccine-preventable diseases.
NFID also released a collection of frequently asked questions (FAQs) about the COVID-19 vaccines. Health care professionals and the general public can use this resource for information about mRNA vaccines, dosing timeframes, vaccine safety and vaccine administration.
HHS Secretary Xavier Becerra sent a letter to insurers and providers clarifying that COVID-19 vaccines and testing must be free for patients.
HHS has also produced a video series detailing the history and science of vaccines. The series is designed to provide background and clarity — via expert commentary and graphic illustration — to help viewers understand how vaccines are developed and the full strength of initiatives such as Operation Warp Speed.
The Trump administration released the COVID-19 Vaccine Distribution Strategy, which includes two documents detailing the distribution strategy and a vaccine program interim playbook.
President Joe Biden released a National Strategy for the COVID-19 Response and Pandemic Preparedness and a fact sheet announcing the goal to administer at least one vaccine shot to 70% of the U.S. adult population by July 4, 2021.
The president also issued a number of executive orders, including:
In addition, President Biden, first lady Jill Biden, Vice President Kamala Karris and second gentleman Doug Emhoff have all publicly received a COVID-19 vaccine to promote the safety and efficacy of the vaccine.
The CDC announced that booster shots are available for all Pfizer-BioNTech or Moderna COVID-19 vaccine recipients who completed their initial series at least 6 months ago.
In addition to this, booster shots are recommended for all recipients of the Janssen (Johnson & Johnson) COVID-19 vaccine who are 18 and older and who were vaccinated two or more months ago.
The latest CDC guidelines allow eligible individuals to choose which vaccine they receive as a booster dose. Some people may have a preference for the vaccine type that they originally received, and others may prefer to get a different booster.
The HHS Office of Intergovernmental and External Affairs has shared the following suggestions from the HHS and the White House on how NPs can prepare for the Pfizer-BioNTech COVID-19 vaccine booster shot administration.
Masks: The CDC currently recommends that those who are not fully vaccinated continue wearing masks in public settings and in large gatherings where other social distancing measures are difficult to maintain. For those who are fully vaccinated, it's recommended to wear a mask in public if you are in an area of substantial or high transmission to maximize protection and prevent the virus from being spread.
The CDC has released interim guidance for health care professionals in the U.S. to combat the spread of this illness, including but not limited to guidance on:
In the U.S., 960,692,671 tests have been reported, according to the CDC, with 91,266,408 reported as positive.
President Biden and Vice President Harris have released a seven-point plan to beat COVID-19. In addition, President Biden issued an Executive Order on January 21 to establish a COVID-19 Pandemic Testing Board and to ensure a sustainable public health workforce for COVID-19 and future health care emergencies.
In anticipation of future approvals and authorizations on pediatric COVID-19 vaccines, the CDC COVID-19 Vaccine Task Force has released a Pediatric COVID-19 Vaccination Operational Planning Guide. This planning guide will help NPs prepare their practices for the implementation of new vaccine procedures for children younger than 12 years old by focusing on key differences between the pediatric program and the one designed to vaccinate adolescents and adults.
The CDC has released a 48-page resource guide entitled COVID-19 Vaccination Field Guide: 12 Strategies for Your Community. The field guide will help NPs quickly implement intervention strategies to promote COVID-19 vaccine confidence and uptake, based on research-proven methods.
NAM and the American Public Health Association have launched a nonaccredited webinar series to explore the current science about COVID-19. Webinar topics include crisis standards of care during COVID-19, the science behind social distancing and the impact of COVID-19 on long-term health.
To address health disparities, particularly brought to light during the COVID-19 pandemic, the National Quality Forum has released The Care We Need, a roadmap to normalize high-quality health care for every person by 2030. The report focuses on opportunities to improve the health outcomes of people and communities, along with recommendations that emphasize the importance of a seamless system of comprehensive, accessible care designed to keep people healthy and well.
PCORI has produced a six-part, nonaccredited webinar series on COVID-19, available at no cost. Topics in the series include how incident command structures can be utilized to coordinate a response to COVID-19, nurse staffing practices and issues and the changing role of telehealth.
In partnership with the U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR) and in collaboration with the National Ebola and Special Pathogens Training and Education Centers (NETEC), Project ECHO has launched a series of COVID-19 Clinical Rounds. These panel discussions are designed to facilitate learning and dialog concerning COVID-19 treatment, and a number of special sessions highlight topics such as pediatrics, personal protective equipment (PPE), long-term care facilities and more.
Human-to-human transmission has been confirmed in China and other countries around the world, including within the U.S. WHO has released daily situation reports monitoring the spread, treatment recommendations and response to the outbreak. It also maintains an updated situation dashboard on COVID-19 cases globally and reports that there have been 607,745,726 confirmed cases and 6,498,747 confirmed deaths worldwide.
The CDC reports that there have been 95,314,517 total cases and 1,047,020 deaths in the U.S.
The United States Census Bureau has created a dashboard to show states' COVID-19 impact planning reports, nationwide demographic and economic analysis and additional data on how the pandemic is impacting communities and Americans across the U.S.
AANP is closely tracking policy developments in response to the COVID-19 pandemic.
AANP is committed to keeping you up to date, including by providing details on federal- and state-issued waivers and flexibilities for NPs and increased access to telehealth. Information included is related to Centers for Medicare and Medicaid Services (CMS) waivers, emergency state actions and licensure information and other policy guidance.
AANP conducted three surveys dedicated to understanding the impact of COVID-19 on NPs:
AANP is compiling educational and clinical information regarding the COVID-19 pandemic, including a look at symptoms, testing, infection control, protection for health care providers and current, approved treatment options and investigational treatments. When available, information on funding and research is also shared.
Three patient education infographics, designed to provide information on common symptoms and tips on protecting oneself and others from COVID-19, are now available for download.
The first cases of the novel (new) coronavirus were reported in Wuhan, China, in December 2019. Describing a respiratory illness with symptoms of fever, cough and shortness of breath, COVID-19 is different than coronaviruses that are already known to circulate among humans, including 229E, NL63, OC43 and HKU1.
COVID-19 also differs from SARS-CoV, first reported in 2002, or MERS-CoV, first reported in 2012. However, genetic analyses have suggested that the COVID-19 may have emerged from a virus related to SARS.
Illness severity has varied, with reports ranging from very mild cases (including some with no reported symptoms) to severe cases resulting in death. Older adults, people who live in nursing homes or long-term care facilities and people with severe underlying health conditions or compromised immune systems reportedly are at higher risk of developing serious COVID-19 illness.